DNB Markets analyst Geir Hiller Holom downgraded BerGenBio to Sell from Hold with a price target of NOK 1, down from NOK 9. The analyst sees the terms of the rights issue financing as "detrimental to the stock" and also struggles to identify substantial share price catalysts for the next 12- 18 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BRRGF: